Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

At its annual artificial intelligence-focused GTC conference in San Jose, Nvidia outlined several collaborations with medtech ...

As the U.S. cuts federal research funding and infrastructure, European countries are strategizing ways to attract top ...

After serving as the director of the National Human Genome Research Institute (NHGRI) for more than 15 years, Eric Green, M.D ...

As a result of the stop work order, Vaxart said it had been forced to lay off 10% of its workforce. The company entered the ...

Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...

About three months after leaving her post as the FDA’s principal deputy commissioner, Namandjé Bumpus, Ph.D., has found a new ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...